These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2895340)

  • 21. Relapse of duodenal ulcer.
    McCloy R
    Br Med J (Clin Res Ed); 1986 Dec; 293(6561):1569-70. PubMed ID: 3099965
    [No Abstract]   [Full Text] [Related]  

  • 22. Recurrent ulcer treated with colloidal bismuth.
    Koo J; Lam SK
    Med J Aust; 1983 Feb; 1(3):103-4. PubMed ID: 6571529
    [No Abstract]   [Full Text] [Related]  

  • 23. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate.
    O'Riordan T; Mathai E; Tobin E; McKenna D; Keane C; Sweeney E; O'Morain C
    Gut; 1990 Sep; 31(9):999-1002. PubMed ID: 2210469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance therapy with colloidal bismuth subcitrate reduces duodenal ulcer relapse.
    Bardhan KD; Singh S; Morris P; Thompson M; Hinchliffe RF; Cary BA; Wall RM; Blakemore CB
    Ital J Gastroenterol Hepatol; 1997 Apr; 29(2):128-34. PubMed ID: 9646192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative study of the efficacy of De-Nol and ranitidine in treating duodenal ulcer].
    Oproiu A; Pospai D; Cociaşu S; Oproiu C
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1988; 40(4):375-84. PubMed ID: 2905519
    [No Abstract]   [Full Text] [Related]  

  • 26. Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with cimetidine.
    Bianchi Porro G; Lazzaroni M; Petrillo M; De Nicola C
    Lancet; 1984 Sep; 2(8404):698. PubMed ID: 6147723
    [No Abstract]   [Full Text] [Related]  

  • 27. [Drug information. New bismuth preparation against presumed cause of gastric ulcer].
    Dahlerup J
    Sygeplejersken; 1989 Nov; 89(46):14-5. PubMed ID: 2617427
    [No Abstract]   [Full Text] [Related]  

  • 28. The influence of relapse rate on the choice of duodenal ulcer therapy.
    Drug Ther Bull; 1987 Oct; 25(20):77-80. PubMed ID: 2890508
    [No Abstract]   [Full Text] [Related]  

  • 29. Colloidal bismuth subcitrate in peptic ulcer disease.
    Tytgat GN
    S Afr Med J; 1986 Jul; 70(1):31-3. PubMed ID: 3523793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Campylobacter pyloridis, gastritis, and peptic ulceration.
    Goodwin CS; Armstrong JA; Marshall BJ
    J Clin Pathol; 1986 Apr; 39(4):353-65. PubMed ID: 3517070
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antral Helicobacter pylori, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism.
    Levi S; Beardshall K; Swift I; Foulkes W; Playford R; Ghosh P; Calam J
    BMJ; 1989 Dec; 299(6714):1504-5. PubMed ID: 2514864
    [No Abstract]   [Full Text] [Related]  

  • 32. Peptic ulcer treatment today--is there a role for maintenance therapy?
    Breslin NP; O'Morain C
    Ital J Gastroenterol Hepatol; 1997 Apr; 29(2):116-21. PubMed ID: 9646190
    [No Abstract]   [Full Text] [Related]  

  • 33. Monotherapy or polychemotherapy in the treatment of Campylobacter pylori-related gastroduodenal disease.
    Börsch G; Mai U; Müller KM
    Scand J Gastroenterol Suppl; 1988; 142():101-6. PubMed ID: 3166527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Helicobacter pylori positive resistant duodenal ulcers.
    Guslandi M
    Gut; 1993 Nov; 34(11):1646-7; author reply 1647-8. PubMed ID: 8244159
    [No Abstract]   [Full Text] [Related]  

  • 35. [Current insights in the pathogenesis and treatment of duodenal ulcer].
    Beker JA; Koek GH
    Ned Tijdschr Geneeskd; 1991 Jan; 135(3):107-8. PubMed ID: 1996162
    [No Abstract]   [Full Text] [Related]  

  • 36. Resistant duodenal ulcer: when, why and what to do?
    Walt RP; Daneshmend TK
    Postgrad Med J; 1988 May; 64(751):369-72. PubMed ID: 2904675
    [No Abstract]   [Full Text] [Related]  

  • 37. [Bismuth preparations in the treatment of patients with gastric and duodenal ulcer disease].
    Maev IV; Samsonov AA; Golubev NN
    Klin Med (Mosk); 2008; 86(9):57-63. PubMed ID: 19048841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Campylobacter pylori and ulcer recurrence.
    Bianchi Porro G; Lazzaroni M
    Lancet; 1988 Mar; 1(8585):593. PubMed ID: 2894530
    [No Abstract]   [Full Text] [Related]  

  • 39. [Effect of bismuth salts in elimination of Helicobacter pylori from gastric mucosa in patients with duodenal ulcer].
    Romańczyk T; Nowakowska-Duława E; Nowakowska M; Rogala-Zawada D; Kłuciński P
    Med Dosw Mikrobiol; 1993; 45(2):209-12. PubMed ID: 8309299
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of tripotassium-dicitrato-bismuthate (TDB) and cimetidine in peptic ulcer disease, a control study of 40 gastric ulcer and 80 duodenal ulcer.
    Chearanai O; Kachintorn U; Plengvanit U
    J Med Assoc Thai; 1987 Apr; 70(4):176-80. PubMed ID: 3612003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.